Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis

Br J Haematol. 2014 Oct;167(1):144-6. doi: 10.1111/bjh.12948. Epub 2014 May 26.
No abstract available

Keywords: acute myeloid leukaemia; clinical haematology; haematological malignancies; myelofibrosis.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Janus Kinases / antagonists & inhibitors
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / etiology*
  • Nitriles
  • Primary Myelofibrosis / drug therapy*
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrazoles / adverse effects*
  • Pyrimidines
  • Sarcoma, Myeloid / diagnosis
  • Sarcoma, Myeloid / etiology*

Substances

  • Antineoplastic Agents
  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinases